---
title: "Novocure Q2 FY26 net loss narrows to USD 15.66 million; revenue rises 16% to USD 183.58 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293603045.md"
description: "Novocure reported Q2 FY26 results with net revenues rising 16% YoY to USD 183.58 million and a narrowed net loss of USD 15.66 million. Gross margin expanded by 4 percentage points to 78%, aided by a tariff refund. Non-GAAP adjusted EBITDA turned positive at USD 10.8 million, while active patients increased 18% globally to 5,128."
datetime: "2026-07-23T11:01:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293603045.md)
  - [en](https://longbridge.com/en/news/293603045.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293603045.md)
generator: "portal-rs"
---

# Novocure Q2 FY26 net loss narrows to USD 15.66 million; revenue rises 16% to USD 183.58 million

-   Novocure posted Q2 net revenues up 16% year over year to USD 183.6 million, while net loss narrowed to USD 15.7 million. \* Gross margin widened 4 percentage points to 78%, helped by a USD 4.9 million tariff refund and lower array costs. \* Operating loss narrowed to USD 10.6 million, while financial results swung to a USD 1.9 million net expense on lower interest income. \* Non-GAAP adjusted EBITDA turned positive at USD 10.8 million from a loss a year earlier. \* Active patients rose 18% globally to 5,128, including 285 on Optune Pax in the U.S. following its FDA approval in the first quarter. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001645113-26-000062), on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NVCR.US](https://longbridge.com/en/quote/NVCR.US.md)

## Related News & Research

- [Novocure says Phase 3 TRIDENT glioblastoma trial misses overall survival endpoint for earlier TTFields use](https://longbridge.com/en/news/290185824.md)
- [NovoCure (NVCR) Breaks Out on Q2 2026 Earnings - Optune Pax Driving Recovery](https://longbridge.com/en/news/293689613.md)
- [Flexsteel Q4 2026 Earnings Preview](https://longbridge.com/en/news/296031749.md)
- [Norcod to webcast Q2 and first-half 2026 results presentation](https://longbridge.com/en/news/296225973.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**